Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to Post $3.55 Earnings Per Share

Analysts predict that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will announce earnings per share of $3.55 for the current quarter, Zacks reports. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $3.76 and the lowest estimate coming in at $2.96. Jazz Pharmaceuticals reported earnings per share of $3.58 during the same quarter last year, which would suggest a negative year-over-year growth rate of 0.8%. The business is expected to report its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year earnings of $14.99 per share for the current year, with EPS estimates ranging from $14.82 to $15.25. For the next fiscal year, analysts anticipate that the company will report earnings of $17.02 per share, with EPS estimates ranging from $15.64 to $18.06. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.16 by $0.49. The business had revenue of $534.13 million for the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.49 EPS.

Several analysts recently issued reports on JAZZ shares. BMO Capital Markets set a $208.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 3rd. Mizuho set a $148.00 price target on Jazz Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, July 3rd. Evercore ISI restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, August 12th. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Finally, Barclays boosted their price target on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $176.53.

In other news, Director Catherine A. Sohn sold 726 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $135.65, for a total transaction of $98,481.90. Following the completion of the sale, the director now directly owns 9,574 shares in the company, valued at approximately $1,298,713.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Paul Treacy sold 4,371 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Jazz Pharmaceuticals by 5.0% during the 2nd quarter. Royal Bank of Canada now owns 174,730 shares of the specialty pharmaceutical company’s stock worth $24,909,000 after buying an additional 8,247 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Jazz Pharmaceuticals by 56.3% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,651 shares of the specialty pharmaceutical company’s stock worth $233,000 after buying an additional 595 shares in the last quarter. MAI Capital Management raised its holdings in shares of Jazz Pharmaceuticals by 2.2% during the 2nd quarter. MAI Capital Management now owns 4,364 shares of the specialty pharmaceutical company’s stock worth $622,000 after buying an additional 96 shares in the last quarter. Eaton Vance Management raised its holdings in shares of Jazz Pharmaceuticals by 4.8% during the 2nd quarter. Eaton Vance Management now owns 154,860 shares of the specialty pharmaceutical company’s stock worth $22,077,000 after buying an additional 7,033 shares in the last quarter. Finally, United Services Automobile Association raised its holdings in shares of Jazz Pharmaceuticals by 178.3% during the 2nd quarter. United Services Automobile Association now owns 38,725 shares of the specialty pharmaceutical company’s stock worth $5,521,000 after buying an additional 24,808 shares in the last quarter. Hedge funds and other institutional investors own 89.59% of the company’s stock.

JAZZ traded up $3.44 during trading on Friday, hitting $134.83. The stock had a trading volume of 241,900 shares, compared to its average volume of 422,353. The company has a 50 day moving average price of $138.13 and a 200-day moving average price of $134.53. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 11.02, a P/E/G ratio of 1.10 and a beta of 1.14. Jazz Pharmaceuticals has a one year low of $113.52 and a one year high of $176.73. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.